高危霍奇金淋巴瘤患儿中的肿瘤特异性免疫应答与生物标志物
研究基于COG AHOD1331随机3期试验,纳入2至21岁新诊断高危经典型霍奇金淋巴瘤患者,比较标准化疗ABVE-PC与维布妥昔单抗联合AVE-PC方案。结果显示两种方案均与有利的细胞因子环境相关,均增加肿瘤抗原特异性T细胞应答并降低sCD30、sCD163和TARC水平,该环境可能有助于后续细胞与免疫治疗的应用。
要点
- 在COG AHOD1331试验中,含或不含抗CD30抗体药物偶联物维布妥昔单抗的化疗均与有利的细胞因子环境相关。
- 两个治疗组均增加肿瘤抗原特异性T细胞应答,并降低sCD30、sCD163和TARC水平。
- 该治疗环境可能有助于针对经典型霍奇金淋巴瘤的进一步细胞与免疫治疗应用。
核心结论
- COG AHOD1331试验中经典型霍奇金淋巴瘤的治疗产生了有利于抗肿瘤免疫应答的环境,可能有助于进一步细胞与免疫治疗的应用。
研究设计与样本
- COG AHOD1331是一项随机3期试验,纳入2至21岁新诊断高危经典型霍奇金淋巴瘤患者,比较标准化疗ABVE-PC与维布妥昔单抗联合AVE-PC方案并采用应答适应性放疗。
- 研究评估外周血中T细胞特异性免疫应答以及细胞因子和趋化因子谱,包括可溶性CD30(sCD30)、sCD163和胸腺活化调节趋化因子(TARC)水平与无事件生存的关系。
主要发现
- 含或不含抗CD30抗体药物偶联物维布妥昔单抗的化疗均与有利的细胞因子环境相关。
- 两个治疗组均增加肿瘤抗原特异性T细胞应答。
- 两个治疗组均降低sCD30、sCD163和TARC水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an unmet need to examine antitumor immune responses and predictive biomarkers in the peripheral blood to guide effective combination immunotherapies in classical Hodgkin lymphoma (cHL). We sought to evaluate T-cell specific immune responses as well as cytokine and chemokine profiles including levels of soluble CD30 (sCD30), sCD163, and thymus and activation-regulated chemokine (TARC) in relation to event-free survival in patients with cHL. The Children's Oncology Group (COG) clinical trial AHOD1331 was a randomized phase 3 trial for patients with newly diagnosed high-risk cHL, aged 2 to 21 years, which compared standard chemotherapy and doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) with brentuximab vedotin (Bv) and AVE-PC with response adapted radiation. Our results demonstrate that chemotherapy with or without addition of anti-CD30 antibody-drug conjugate Bv is associated with a favorable cytokine environment for cellular and immunotherapies. Treatment of cHL on both arms increased tumor antigen-specific T-cell responses and resulted in decreased levels of sCD30, sCD163, and TARC. We demonstrate that treatment of cHL on COG AHOD1331 produced an environment that favors antitumor immune response, which may aid in application of further cellular and immunotherapies targeting cHL. This trial was registered at www.ClinicalTrials.gov as #NCT02166463.
引用
- Toner K, Renfro LA, Dave H, et al. Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma. Blood Adv. 2026. PMID: 40990939. doi:10.1182/bloodadvances.2025016797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。